DermTech - DMTK Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for DermTech in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DMTK shares.
View DMTK analyst ratings or view top-rated stocks.

4 Wall Street analysts have issued twelve-month price targets for DermTech's shares. Their DMTK share price forecasts range from $14.00 to $48.00. On average, they expect the company's stock price to reach $24.17 in the next twelve months. This suggests a possible upside of 255.4% from the stock's current price.
View analysts price targets for DMTK or view top-rated stocks among Wall Street analysts.

DermTech's stock was trading at $15.80 at the start of the year. Since then, DMTK stock has decreased by 57.0% and is now trading at $6.80.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our DMTK earnings forecast.

DermTech, Inc. (NASDAQ:DMTK) announced its earnings results on Tuesday, November, 9th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.65) by $0.03. The business had revenue of $3.03 million for the quarter, compared to analyst estimates of $3.40 million. DermTech had a negative net margin of 748.29% and a negative trailing twelve-month return on equity of 49.02%. During the same quarter in the prior year, the company earned ($0.50) earnings per share.

Based on aggregate information from My MarketBeat watchlists, some companies that other DermTech investors own include Pfizer (PFE), CrowdStrike (CRWD), DocuSign (DOCU), ONEOK (OKE), Intel (INTC), U.S. Xpress Enterprises (USX), Valero Energy (VLO), Hello Group (MOMO), AVEO Pharmaceuticals (AVEO) and Camping World (CWH).

DermTech trades on the NASDAQ under the ticker symbol "DMTK."

DermTech's stock is owned by many different retail and institutional investors. Top institutional shareholders include Victory Capital Management Inc. (3.65%), AEGON ASSET MANAGEMENT UK Plc (1.64%), Landscape Capital Management L.L.C. (1.36%), Epiq Partners LLC (0.67%), King Luther Capital Management Corp (0.65%) and Oak Ridge Investments LLC (0.48%). Insiders that own company stock include Burkhard Jansen, Claudia Ibarra, Enrico Picozza, Herm Rosenman, John Dobak, Kevin M Sun, Kevin M Sun, Matthew L Posard, Mutual Insurance Co Donegal, Rtw Investments, Lp, Scott R Pancoast and Todd Michael Wood.
View institutional ownership trends.

Shares of DMTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DMTK stock can currently be purchased for approximately $6.80.

DermTech (NASDAQ:DMTK) has a market capitalization of $204.27 million and generates $11.84 million in revenue each year. The company earns $-78,330,000.00 in net income (profit) each year or ($3.56) on an earnings per share basis.

The company employs 255 workers across the globe.

DermTech's mailing address is 11099 N. Torrey Pines Road Suite 100, La Jolla CA, 92037. The official website for the company is www.dermtech.com. The company can be reached via phone at (858) 450-4222 or via email at investorrelations@dermtech.com.